Robert Rosen

Robert Rosen is the current director at Odonate Therapeutics, and was previously the president at Heron Therapeutics from July 2012 to February 2019. Robert was responsible for building out all commercial functions and launching 2 brands that achieved peak sales of $100M within 36 months. Robert also supported multiple raises and roadshows that generated over $750M. Under their leadership, shareholder value increased from $62M to $1.3B over a six year period.

Prior to their role at Heron Therapeutics, Rosen was the global head of oncology at Nankwest from January 2014 to January 2015. In this role, they were responsible for the global launch of Sorafanib, Regorafanib and Alpharedin across multiple tumor types. Robert managed a commercial organization of 500 professionals with an operating budget of $110M that generated $750M in revenue. Robert was also a critical member of multiple partnership committees, including those with Onyx Pharmaceuticals, Algeta therapeutics, Oncomed Pharmaceuticals, and Genzyme.

Robert Rosen graduated from Northeastern University.